2Q EARNINGS: Abbott's pharma sales grow in emerging markets
This article was originally published in Scrip
Foreign exchange rates caused a 0.1% year-over-year decline in Abbott's established pharmaceuticals sales to $1.2bn during the second quarter, but sales for the company's branded generics in emerging markets – the pharma portfolio that isn't being sold to Mylan – jumped 4.4% to $616m.
You may also be interested in...
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.